PhewyPompipi的个人主页 - 老虎社区

PhewyPompipi

PhewyPompipi

暂无个人介绍

IP属地：未知

12关注

9粉丝

0主题

0勋章

2021-12-01

BioNTech has good potential. So there's really no reason for investors to dump the stock. Once the test results are out, prepare for it to soar!

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

2021-11-29

It's all good news to us investors.

BioNTech Is Working On an Omicron Version of Its Covid Shot

2021-11-12

$BioNTech SE(BNTX)$Seriously? Why is this tanking when more vaccines are needed now for 3rd booster shots as well as for 5 - 11yo? Frustrating...😑

2021-11-05

Wth...

Vaccine stocks slipped after Pfizer announced its good news

2021-10-22

$BioNTech SE(BNTX)$up and up yeah! Good momentum, BioNTech, keep it going!

2021-10-14

What about vaccine stocks...they are a little worrisome now with its constant yoyo prices?

Buying The Dip Is Dead

2021-10-10

Let's hope for the best soon!

2022 Could Be A Great Year

2021-10-08

$Apple(AAPL)$Hopefully more bullish run tonight.

2021-10-01

Is this why...for BioNTech investors = Negative news?

Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News

2021-10-01

$BioNTech SE(BNTX)$It's like I see no hope at all...manage to average down but the price plummet even further today.

2021-09-28

$BioNTech SE(BNTX)$time to faint???

2021-09-25

$BioNTech SE(BNTX)$Why is the stock price always disappointing, past its heyday? Holding on is so draining...

2021-09-22

Happy!

Apple sees 5M iPhone 13 pre-orders in China--report

2021-09-20

$Apple(AAPL)$Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?

2021-09-01

Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...

@Kel1:$BioNTech SE(BNTX)$Will this recover?

2021-08-30

$Apple(AAPL)$Could it go up to $159?/$160 mark? 😍

2021-08-23

Hopefully it will rise to about its pre-glory price of $480+?

抱歉，原内容已删除

2021-08-17

$Apple(AAPL)$will it go to $160? To hold or sell?

2021-08-16

$BioNTech SE(BNTX)$what is happening? Why was it doing well last week and today opening mkt and it sink so bad?

2021-08-13

Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?

BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4087475573507020,"uuid":"4087475573507020","gmtCreate":1624372765357,"gmtModify":1624500741691,"name":"PhewyPompipi","pinyin":"phewypompipi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":12,"tweetSize":40,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":609590806,"gmtCreate":1638291592848,"gmtModify":1638291592918,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"BioNTech has good potential. So there's really no reason for investors to dump the stock. Once the test results are out, prepare for it to soar!","listText":"BioNTech has good potential. So there's really no reason for investors to dump the stock. Once the test results are out, prepare for it to soar!","text":"BioNTech has good potential. So there's really no reason for investors to dump the stock. Once the test results are out, prepare for it to soar!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609590806","repostId":"1190156196","repostType":4,"repost":{"id":"1190156196","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","JNJ":"强生"},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600451700,"gmtCreate":1638191764950,"gmtModify":1638191765142,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"It's all good news to us investors.&nbsp;","listText":"It's all good news to us investors.&nbsp;","text":"It's all good news to us investors.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600451700","repostId":"1173904581","repostType":4,"repost":{"id":"1173904581","pubTimestamp":1638186226,"share":"https://www.laohu8.com/m/news/1173904581?lang=&edition=full","pubTime":"2021-11-29 19:43","market":"us","language":"en","title":"BioNTech Is Working On an Omicron Version of Its Covid Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1173904581","media":"Bloomberg","summary":"BioNTech SE is working to adapt its Covid-19 vaccine to address the omicron variant and expects to h","content":"<p>BioNTech SE&nbsp;is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary.</p>\n<p>BioNTech SE&nbsp;stock&nbsp;jumped&nbsp;5%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/df27de31843e0340df06283dfd4547ae\" tg-width=\"850\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>The company has started development in order to move as quickly as possible, BioNTech said in a statement. The first steps of developing a new vaccine overlap with the&nbsp;research&nbsp;necessary in order to evaluate whether a new shot will be needed -- a process that began last Thursday as soon as&nbsp;news&nbsp;of the new variant began to spread around the world.</p>\n<p>The German biotech and its Covid vaccine partner&nbsp;Pfizer Inc.&nbsp;put plans into place months ago to ensure a new version of their shot could ship within 100 days if necessary. The omicron variant has raised concerns around the world, with countries implementing travel bans to buy time as researchers race to study whether it will evade vaccines and spread more rapidly. It will probably take weeks to understand the full impact of the variant, scientists have said.</p>\n<p>Moderna Inc., which makes another messenger-RNA vaccine for Covid, has begun a similar&nbsp;process&nbsp;of evaluation and development, should a new shot be necessary. Both companies have said it should become clear within weeks whether an adapted vaccine will be needed.</p>\n<p>Vaccinated people should still be protected, depending on how long ago they got their shots, and for now the best advice is to take one of the current Covid vaccines, Moderna Chief Medical Officer Paul Burton said on Sunday on the BBC’s “Andrew Marr Show.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Is Working On an Omicron Version of Its Covid Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Is Working On an Omicron Version of Its Covid Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 19:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-29/biontech-is-working-on-an-omicron-version-of-its-covid-shot?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech SE is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary.\nBioNTech SE stock jumped 5% in premarket ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-29/biontech-is-working-on-an-omicron-version-of-its-covid-shot?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-29/biontech-is-working-on-an-omicron-version-of-its-covid-shot?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173904581","content_text":"BioNTech SE is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary.\nBioNTech SE stock jumped 5% in premarket trading.\n\nThe company has started development in order to move as quickly as possible, BioNTech said in a statement. The first steps of developing a new vaccine overlap with the research necessary in order to evaluate whether a new shot will be needed -- a process that began last Thursday as soon as news of the new variant began to spread around the world.\nThe German biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago to ensure a new version of their shot could ship within 100 days if necessary. The omicron variant has raised concerns around the world, with countries implementing travel bans to buy time as researchers race to study whether it will evade vaccines and spread more rapidly. It will probably take weeks to understand the full impact of the variant, scientists have said.\nModerna Inc., which makes another messenger-RNA vaccine for Covid, has begun a similar process of evaluation and development, should a new shot be necessary. Both companies have said it should become clear within weeks whether an adapted vaccine will be needed.\nVaccinated people should still be protected, depending on how long ago they got their shots, and for now the best advice is to take one of the current Covid vaccines, Moderna Chief Medical Officer Paul Burton said on Sunday on the BBC’s “Andrew Marr Show.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870746623,"gmtCreate":1636655711171,"gmtModify":1636655711386,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously? Why is this tanking when more vaccines are needed now for 3rd booster shots as well as for 5 - 11yo? Frustrating...😑","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously? Why is this tanking when more vaccines are needed now for 3rd booster shots as well as for 5 - 11yo? Frustrating...😑","text":"$BioNTech SE(BNTX)$Seriously? Why is this tanking when more vaccines are needed now for 3rd booster shots as well as for 5 - 11yo? Frustrating...😑","images":[{"img":"https://static.tigerbbs.com/7023799f8e65f048e38dc8f783b6a876","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/870746623","isVote":1,"tweetType":1,"viewCount":982,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846771824,"gmtCreate":1636118254704,"gmtModify":1636118931968,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Wth...","listText":"Wth...","text":"Wth...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846771824","repostId":"1196545101","repostType":2,"repost":{"id":"1196545101","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636114848,"share":"https://www.laohu8.com/m/news/1196545101?lang=&edition=full","pubTime":"2021-11-05 20:20","market":"us","language":"en","title":"Vaccine stocks slipped after Pfizer announced its good news","url":"https://stock-news.laohu8.com/highlight/detail?id=1196545101","media":"Tiger Newspress","summary":"Vaccine stocks slipped after Pfizer announced his good news.Pfizer said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.BioNTech SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly and AstraZeneca fell between 1% and 11%.Whlie Pfizer surged 12% in premarket trading.","content":"<p>Vaccine stocks slipped after Pfizer announced his good news.Pfizer&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.</p>\n<p>BioNTech&nbsp;SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly&nbsp;and&nbsp;AstraZeneca&nbsp;fell&nbsp;between 1% and 11%.Whlie&nbsp;Pfizer&nbsp;surged&nbsp;12%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8a70ae8e53167b1da5670c9bd985e930\" tg-width=\"402\" tg-height=\"664\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks slipped after Pfizer announced its good news</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks slipped after Pfizer announced its good news\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks slipped after Pfizer announced his good news.Pfizer&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.</p>\n<p>BioNTech&nbsp;SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly&nbsp;and&nbsp;AstraZeneca&nbsp;fell&nbsp;between 1% and 11%.Whlie&nbsp;Pfizer&nbsp;surged&nbsp;12%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8a70ae8e53167b1da5670c9bd985e930\" tg-width=\"402\" tg-height=\"664\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","MRNA":"Moderna, Inc.","PFE":"辉瑞","GILD":"吉利德科学","INO":"伊诺维奥制药","VIR":"Vir Biotechnology, Inc.","LLY":"礼来","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","REGN":"再生元制药公司","AZN":"阿斯利康"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196545101","content_text":"Vaccine stocks slipped after Pfizer announced his good news.Pfizer said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.\nBioNTech SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly and AstraZeneca fell between 1% and 11%.Whlie Pfizer surged 12% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853477115,"gmtCreate":1634832939308,"gmtModify":1634832939535,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>up and up yeah!&nbsp;Good momentum, BioNTech, keep it going!","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>up and up yeah!&nbsp;Good momentum, BioNTech, keep it going!","text":"$BioNTech SE(BNTX)$up and up yeah! Good momentum, BioNTech, keep it going!","images":[{"img":"https://static.tigerbbs.com/b0ab025e74b0a0b3b8d7781e53f3f728","width":"1080","height":"2580"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853477115","isVote":1,"tweetType":1,"viewCount":468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":825988159,"gmtCreate":1634190293162,"gmtModify":1634190293162,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"What about vaccine&nbsp;stocks...they are a little worrisome now with its constant yoyo prices?","listText":"What about vaccine&nbsp;stocks...they are a little worrisome now with its constant yoyo prices?","text":"What about vaccine stocks...they are a little worrisome now with its constant yoyo prices?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825988159","repostId":"1111412750","repostType":4,"repost":{"id":"1111412750","pubTimestamp":1634182832,"share":"https://www.laohu8.com/m/news/1111412750?lang=&edition=full","pubTime":"2021-10-14 11:40","market":"us","language":"en","title":"Buying The Dip Is Dead","url":"https://stock-news.laohu8.com/highlight/detail?id=1111412750","media":"seekingalpha","summary":"Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical rea","content":"<p>Summary</p>\n<ul>\n <li>Buying the dip died when the volatility sellers failed to show up.</li>\n <li>There's a mechanical reason why the market has not \"bounced back.\"</li>\n <li>That mechanical reason has broken down due to fundamental shifts.</li>\n</ul>\n<p>The market has been melting, and that \"buy the dip\" mentality seems to be in trouble. There's an excellent reason for why buying the dip hasn't worked, and probably why it won't work this time around either. All you have to do is look at the VIX and the SKEW indexes to understand why.</p>\n<p>Falling volatility has been a lynchpin of propping up the market every time it falters since the COVID low. Every time the market sank, the VIX would spike higher. Then, a swarm of traders would come in looking to short volatility, which would send the VIX lower, pushing the S&amp;P 500 higher. However, that component of the market appears to be gone. The VIX has been steadily rising since June, with higher lows. More recently, the VIX hasn't been able to get below 18, and each drop in the S&amp;P 500 has seen lower highs.</p>\n<p><img src=\"https://static.tigerbbs.com/7d40186560f397cc6ebdc4e85ba18725\" tg-width=\"640\" tg-height=\"397\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Additionally, the SKEW index has cratered in recent weeks. It's because traders that have been betting on volatility falling have likely been shorting at-the-money forms of it, and to hedge those positions, they have been buying out-of-money forms. It's why the SKEW index reached record highs in June as the VIX hit its lows.</p>\n<p>The SKEW index wasn't rising into June 2021 because traders were trying to hedge against tail risk or an unforeseen event. The SKEW index was rising as a hedge against short volatility positions.</p>\n<p>If volatility sellers do not return to this market, then a big piece of why the market always has been able to bounce back so quickly on every dip will be gone. Buying the dip will simply not work.</p>\n<p><img src=\"https://static.tigerbbs.com/d92c33e67c289d5c9d1e8d0d6ec74b5d\" tg-width=\"640\" tg-height=\"397\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>But with QE likely on its way out, financial conditions are likely to tighten as a result. It seems that volatility sellers have gone missing for a good reason. If that's the case, the considerable risk in the market isn't going to be the fear of missing out. The substantial risk is a meltdown, not all that&nbsp;dissimilar to that of 2018, which I have noted on several occasions many of the same similarities of today to back then.</p>\n<p>The dollar index may be a big piece of that. It has been surging higher, and that the S&amp;P 500 has been trading precisely the opposite to the dollar's move. When the dollar has been strengthening, the S&amp;P 500 has been falling and vice versa. The&nbsp;dollar is telling us that tapering&nbsp;is coming and very soon. The stock market knows what this means too, and it isn't good for stocks.</p>\n<p>The two-year Treasury rate has also been creeping higher and now stands at more than 35 bps. The two-year most likely needs to rise much more if the Fed is tapering. By the time the QE taper ended in October 2014, the two-year was around 50 to 60 bps. That means the&nbsp;two-year&nbsp;now has further to climb as this process commences potentially as soon as the November FOMC meeting.</p>\n<p>Despite the stronger dollar, the 10-year has been falling, and that's because the market is picking up on what I have been telling you for months. Growth rates here in the US and around the globe have been slowing and are now near stall speed. They have gotten so slow here in the US that the Atlanta Fed GDPNow is now projecting just a 1.3% third quarter growth rate, an enormous drop from the second-quarter reading of 6.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/ce210603773584da38e4fbf054f31ba9\" tg-width=\"640\" tg-height=\"480\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The market knows that a strong dollar in regular times exports inflationary forces aboard in countries that buy commodities, finances debt, or conduct business in dollars. It's a global growth killer. On top of that, rising prices for things like energy are already likely to slow growth, and now with the dollar rising, it makes the problem even more prominent. It is driving the rates on the long-end of the curve lower and flattening the yield curve.</p>\n<p>This time is different from previous pullbacks. This is why this time the pullback is only in its early phases. Earnings estimates have started to come down, and they are likely to come down further because if one thing is crystal clear, GDP growth expectations were way off base, and means that it is highly likely that&nbsp;earnings estimates&nbsp;are way off base, which means earnings growth rates will be heading lower or top of what they have declined.</p>\n<p><img src=\"https://static.tigerbbs.com/b784f4142c7b91a6c36b4c8d263db047\" tg-width=\"640\" tg-height=\"480\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>It's just a matter of when the stock market realizes that a Fed tapering event will push the dollar index even higher at the worst possible time resulting in a massive global growth scare. Perhaps the biggest reason why the volatility sellers have left the building.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buying The Dip Is Dead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuying The Dip Is Dead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4459696-buying-the-dip-is-dead><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical reason why the market has not \"bounced back.\"\nThat mechanical reason has broken down due to fundamental...</p>\n\n<a href=\"https://seekingalpha.com/article/4459696-buying-the-dip-is-dead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://seekingalpha.com/article/4459696-buying-the-dip-is-dead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111412750","content_text":"Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical reason why the market has not \"bounced back.\"\nThat mechanical reason has broken down due to fundamental shifts.\n\nThe market has been melting, and that \"buy the dip\" mentality seems to be in trouble. There's an excellent reason for why buying the dip hasn't worked, and probably why it won't work this time around either. All you have to do is look at the VIX and the SKEW indexes to understand why.\nFalling volatility has been a lynchpin of propping up the market every time it falters since the COVID low. Every time the market sank, the VIX would spike higher. Then, a swarm of traders would come in looking to short volatility, which would send the VIX lower, pushing the S&P 500 higher. However, that component of the market appears to be gone. The VIX has been steadily rising since June, with higher lows. More recently, the VIX hasn't been able to get below 18, and each drop in the S&P 500 has seen lower highs.\n\nAdditionally, the SKEW index has cratered in recent weeks. It's because traders that have been betting on volatility falling have likely been shorting at-the-money forms of it, and to hedge those positions, they have been buying out-of-money forms. It's why the SKEW index reached record highs in June as the VIX hit its lows.\nThe SKEW index wasn't rising into June 2021 because traders were trying to hedge against tail risk or an unforeseen event. The SKEW index was rising as a hedge against short volatility positions.\nIf volatility sellers do not return to this market, then a big piece of why the market always has been able to bounce back so quickly on every dip will be gone. Buying the dip will simply not work.\n\nBut with QE likely on its way out, financial conditions are likely to tighten as a result. It seems that volatility sellers have gone missing for a good reason. If that's the case, the considerable risk in the market isn't going to be the fear of missing out. The substantial risk is a meltdown, not all that dissimilar to that of 2018, which I have noted on several occasions many of the same similarities of today to back then.\nThe dollar index may be a big piece of that. It has been surging higher, and that the S&P 500 has been trading precisely the opposite to the dollar's move. When the dollar has been strengthening, the S&P 500 has been falling and vice versa. The dollar is telling us that tapering is coming and very soon. The stock market knows what this means too, and it isn't good for stocks.\nThe two-year Treasury rate has also been creeping higher and now stands at more than 35 bps. The two-year most likely needs to rise much more if the Fed is tapering. By the time the QE taper ended in October 2014, the two-year was around 50 to 60 bps. That means the two-year now has further to climb as this process commences potentially as soon as the November FOMC meeting.\nDespite the stronger dollar, the 10-year has been falling, and that's because the market is picking up on what I have been telling you for months. Growth rates here in the US and around the globe have been slowing and are now near stall speed. They have gotten so slow here in the US that the Atlanta Fed GDPNow is now projecting just a 1.3% third quarter growth rate, an enormous drop from the second-quarter reading of 6.7%.\n\nThe market knows that a strong dollar in regular times exports inflationary forces aboard in countries that buy commodities, finances debt, or conduct business in dollars. It's a global growth killer. On top of that, rising prices for things like energy are already likely to slow growth, and now with the dollar rising, it makes the problem even more prominent. It is driving the rates on the long-end of the curve lower and flattening the yield curve.\nThis time is different from previous pullbacks. This is why this time the pullback is only in its early phases. Earnings estimates have started to come down, and they are likely to come down further because if one thing is crystal clear, GDP growth expectations were way off base, and means that it is highly likely that earnings estimates are way off base, which means earnings growth rates will be heading lower or top of what they have declined.\n\nIt's just a matter of when the stock market realizes that a Fed tapering event will push the dollar index even higher at the worst possible time resulting in a massive global growth scare. Perhaps the biggest reason why the volatility sellers have left the building.","news_type":1},"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828104978,"gmtCreate":1633856750164,"gmtModify":1633856750274,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Let's hope for the best soon!","listText":"Let's hope for the best soon!","text":"Let's hope for the best soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/828104978","repostId":"1194780749","repostType":4,"repost":{"id":"1194780749","pubTimestamp":1633828304,"share":"https://www.laohu8.com/m/news/1194780749?lang=&edition=full","pubTime":"2021-10-10 09:11","market":"us","language":"en","title":"2022 Could Be A Great Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1194780749","media":"seekingalpha","summary":"Economies are reaccelerating as the number of Delta cases and death have peaked.We could have a great year in 2022 if our government could get its act together.We have concentrated on the producers that will benefit from a robust global economy and tech companies benefitting from the digitalization boom.Even though we are rapidly putting the delta variant in the rear-view mirror, financial markets are struggling due to a lack of leadership in D.C. We have shortages and supply line issues that ha","content":"<p>Summary</p>\n<ul>\n <li>Economies are reaccelerating as the number of Delta cases and death have peaked.</li>\n <li>We could have a great year in 2022 if our government could get its act together.</li>\n <li>We have concentrated on the producers that will benefit from a robust global economy and tech companies benefitting from the digitalization boom.</li>\n</ul>\n<p>Even though we are rapidly putting the delta variant in the rear-view mirror, financial markets are struggling due to a lack of leadership in D.C. We have shortages and supply line issues that hamper production and profitability. All of this will pass.</p>\n<p>What is the problem? Our government is dysfunctional, and we need leadership, especially now, to handle the myriad of domestic and foreign issues facing all of us. We will muddle through and finally get a much-needed traditional infrastructure bill and possibly a scaled-down $2 trillion social spending bill along with lower-than-expected punitive tax increases, this year but 2022 could be a great year, not just a very good year, if only we worked together.</p>\n<p>We have not altered our view that S&amp;P earnings could exceed $220/share in 2022 and $235/share in 2023 as operating margins hit nearly 14% in 2023, up from 11.5% in 2019. Why? Corporations have learned to do more with less during the pandemic; shortages and supply line issues will ease, and substantial increases in technology spending will go a long way, offsetting higher labor costs while improving operations/efficiencies on all levels. Powell will be right that higher inflationary pressures will be transitory, but it may take longer to normalize. We will continue to have accommodative fiscal and monetary policies in 2022. Not a bad market scenario, so use corrections as opportunities to add to your positions. So, as I've said before, invest, don't trade.</p>\n<p>Economies are reaccelerating as the number of Delta cases and death have peaked. Domestic cases have declined 23% and deaths 13% over the 14 days and 17% and 14%, respectively, globally. More than 6.43 billion doses have been administered globally across 184 countries at a daily rate of 28.7 million doses per day. In the U.S., 398 million doses have been given so far at an elevated rate of 931,983 doses per day.</p>\n<p>We still see over 75% of the global population vaccinated within six months and herd immunity sooner. Pfizer(NYSE:PFE)filed Thursday with the FDA its vaccine for children ages 5-11, bringing shots for all school-age children closer, which will boost the economy as parents can return to work. We expect that both Pfizer and Merck's(NYSE:MRK)filings with the FDA will be approved well before year-end. All good news!</p>\n<p>The Fed is itching to start tapering, ending its extraordinary monetary support, which is no longer needed as the economy is on firm footing, and it appears that the Delta variant is subsiding. Unfortunately, Powell and the Fed have been called out for oversight over board members' trading. Two governors have already resigned, and we expect one more may leave shortly. Tapering will probably begin before year-end if the next employment report improves from September and be finished by the third quarter of 2022.</p>\n<p>Again, tapering is NOT tightening, and we do not expect the Fed to start hiking the funds' rate until early 2023. The \"real\" funds' rate will be negative for some time which is NOT tightening at all. By the way, we disagree with Elizabeth Warren's criticism of Chairman Powell and hope that he is renominated next year. The bottom line is that the Fed will remain your friend for at least another 18 months. Don't fight the Fed!</p>\n<p>We are so frustrated by what is happening in D.C. It is all about politics, no surprise, and not about doing what is best for this country. Why do we always have to go to the brink before action is taken? That is precisely what happened this week when the Republicans caved and offered a two-month short-term debt limit extension letting the Dems off the hook from going the route of reconciliation. It passed Thursday night. Daily negotiations continue for the massive social infrastructure program. It will be much smaller than initially proposed, closer to $2 trillion rather than $3.5 trillion. We expect the individual and corporate tax increases to be much more reasonable than initially proposed, which is a clear positive for the economy and financial markets.</p>\n<p>The domestic economy is recovering from the Delta variant, which penalized growth during the summer months. The areas hit most over the summer; travel, dining, and leisure are coming back strongly, as evidenced by the recovery in the high-frequency data.</p>\n<p>Other recent data points include: initial jobless claims fell more than expected to 326,000; the index of consumer sentiment rose in September to 72.9, current economic conditions increased to 80.1, and consumer expectations rose to 68.1; the September Manufacturing PMI increased to 61.1, new orders to 66.7, employment up to 50.1, supplier deliveries to 73.4 and prices index increased to 81.2; the services index grew for the 15th month hitting 60.1, new orders at 63.2, employment at 53.7 and supplier deliveries at 69.6; new orders for manufactured goods increased 1.2% while shipments rose 0.1% and unfilled orders increased 1.0%; and the trade deficit widened to $73.3 billion as imports increased more rapidly than exports due to the strength of the domestic economy.</p>\n<p>Growth and profitability would be even more robust if not for shortages and supply line issues. But that will turn around in 2022 and be a big plus. The September employment data was disappointing with only 194,000 jobs created. The private sector did better adding 317,000 jobs while the public sector lost 123,000 jobs. Interestingly the unemployment rate fell to 4.8% which is the Fed's year-end target as the participation rate declined to 61.6. Hourly earnings rose 0.6% and are up 4.3% in the year through August. The Fed will most likely wait to see the next employment report before beginning tapering.</p>\n<p>The Eurozone economy has finally exceeded pre-covid levels, with most of the 20 indices that we monitor accelerating in recent weeks as cases/deaths have declined meaningfully. Shortages and supply line issues have hampered production while increasing inflationary pressures and won't ease until mid-2022. Energy costs are a real problem and may penalize growth next year. Unfortunately, OPEC opted against a big output boost lifting production by only 400,000 barrels/day, which will not be enough to limit further price increases, especially if we have a cold winter. And natural gas prices have gone through the roof, which will crimp consumer spending and hurt corporate operating margins.</p>\n<p>The global economy is improving as the number of covid cases, and deaths have peaked. Growth would even be more robust if not for shortages and supply line issues, but that will reverse as we move through 2022.</p>\n<p>Investment Conclusions</p>\n<p>Thursday, there was a massive sigh of relief when Congress agreed to extend the debt limit two months, ending the stalemate. We expect the Dems to coalesce around a roughly $2 trillion social infrastructure bill that will permit passage of the much-needed $1 trillion traditional infrastructure bill. What is a government? Fiscal policy will remain stimulative for years to come.</p>\n<p>Then we have a monetary policy. We expect the Fed to remain accommodative for a few more years. We do expect tapering to begin before year-end if the November employment report improves from the last one, but we do&nbsp;<b>not</b>&nbsp;see a rate hike until 2023, and even then, the \"real\" funds' rate will be negative, which is not restrictive at all.</p>\n<p>Shortages and supply line issues have played havoc on production and profitability for many industries/companies around the world in 2021, but this will reverse as we move through 2022, creating opportunities for investors willing to look over the valley.</p>\n<p>The bottom line is that we could have a great year in 2022 if our government could get its act together. The key remains keeping the coronavirus out of the picture, so we must vaccinate all the unvaccinated.</p>\n<p>While we have not seen many changes in our portfolio over the last few months, we have concentrated on the producers that will benefit from a robust global economy and tech companies benefitting from the digitalization boom. We recently added some financials and energy companies as we expect the yield curve to steepen more than previously anticipated. Higher energy prices are immediately ahead as demand outstrips supply. Next year, the big story will be the significant increase in dividends and buybacks well above the historical trend.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2022 Could Be A Great Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2022 Could Be A Great Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-10 09:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4459137-2022-could-be-a-great-year><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nEconomies are reaccelerating as the number of Delta cases and death have peaked.\nWe could have a great year in 2022 if our government could get its act together.\nWe have concentrated on the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4459137-2022-could-be-a-great-year\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://seekingalpha.com/article/4459137-2022-could-be-a-great-year","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1194780749","content_text":"Summary\n\nEconomies are reaccelerating as the number of Delta cases and death have peaked.\nWe could have a great year in 2022 if our government could get its act together.\nWe have concentrated on the producers that will benefit from a robust global economy and tech companies benefitting from the digitalization boom.\n\nEven though we are rapidly putting the delta variant in the rear-view mirror, financial markets are struggling due to a lack of leadership in D.C. We have shortages and supply line issues that hamper production and profitability. All of this will pass.\nWhat is the problem? Our government is dysfunctional, and we need leadership, especially now, to handle the myriad of domestic and foreign issues facing all of us. We will muddle through and finally get a much-needed traditional infrastructure bill and possibly a scaled-down $2 trillion social spending bill along with lower-than-expected punitive tax increases, this year but 2022 could be a great year, not just a very good year, if only we worked together.\nWe have not altered our view that S&P earnings could exceed $220/share in 2022 and $235/share in 2023 as operating margins hit nearly 14% in 2023, up from 11.5% in 2019. Why? Corporations have learned to do more with less during the pandemic; shortages and supply line issues will ease, and substantial increases in technology spending will go a long way, offsetting higher labor costs while improving operations/efficiencies on all levels. Powell will be right that higher inflationary pressures will be transitory, but it may take longer to normalize. We will continue to have accommodative fiscal and monetary policies in 2022. Not a bad market scenario, so use corrections as opportunities to add to your positions. So, as I've said before, invest, don't trade.\nEconomies are reaccelerating as the number of Delta cases and death have peaked. Domestic cases have declined 23% and deaths 13% over the 14 days and 17% and 14%, respectively, globally. More than 6.43 billion doses have been administered globally across 184 countries at a daily rate of 28.7 million doses per day. In the U.S., 398 million doses have been given so far at an elevated rate of 931,983 doses per day.\nWe still see over 75% of the global population vaccinated within six months and herd immunity sooner. Pfizer(NYSE:PFE)filed Thursday with the FDA its vaccine for children ages 5-11, bringing shots for all school-age children closer, which will boost the economy as parents can return to work. We expect that both Pfizer and Merck's(NYSE:MRK)filings with the FDA will be approved well before year-end. All good news!\nThe Fed is itching to start tapering, ending its extraordinary monetary support, which is no longer needed as the economy is on firm footing, and it appears that the Delta variant is subsiding. Unfortunately, Powell and the Fed have been called out for oversight over board members' trading. Two governors have already resigned, and we expect one more may leave shortly. Tapering will probably begin before year-end if the next employment report improves from September and be finished by the third quarter of 2022.\nAgain, tapering is NOT tightening, and we do not expect the Fed to start hiking the funds' rate until early 2023. The \"real\" funds' rate will be negative for some time which is NOT tightening at all. By the way, we disagree with Elizabeth Warren's criticism of Chairman Powell and hope that he is renominated next year. The bottom line is that the Fed will remain your friend for at least another 18 months. Don't fight the Fed!\nWe are so frustrated by what is happening in D.C. It is all about politics, no surprise, and not about doing what is best for this country. Why do we always have to go to the brink before action is taken? That is precisely what happened this week when the Republicans caved and offered a two-month short-term debt limit extension letting the Dems off the hook from going the route of reconciliation. It passed Thursday night. Daily negotiations continue for the massive social infrastructure program. It will be much smaller than initially proposed, closer to $2 trillion rather than $3.5 trillion. We expect the individual and corporate tax increases to be much more reasonable than initially proposed, which is a clear positive for the economy and financial markets.\nThe domestic economy is recovering from the Delta variant, which penalized growth during the summer months. The areas hit most over the summer; travel, dining, and leisure are coming back strongly, as evidenced by the recovery in the high-frequency data.\nOther recent data points include: initial jobless claims fell more than expected to 326,000; the index of consumer sentiment rose in September to 72.9, current economic conditions increased to 80.1, and consumer expectations rose to 68.1; the September Manufacturing PMI increased to 61.1, new orders to 66.7, employment up to 50.1, supplier deliveries to 73.4 and prices index increased to 81.2; the services index grew for the 15th month hitting 60.1, new orders at 63.2, employment at 53.7 and supplier deliveries at 69.6; new orders for manufactured goods increased 1.2% while shipments rose 0.1% and unfilled orders increased 1.0%; and the trade deficit widened to $73.3 billion as imports increased more rapidly than exports due to the strength of the domestic economy.\nGrowth and profitability would be even more robust if not for shortages and supply line issues. But that will turn around in 2022 and be a big plus. The September employment data was disappointing with only 194,000 jobs created. The private sector did better adding 317,000 jobs while the public sector lost 123,000 jobs. Interestingly the unemployment rate fell to 4.8% which is the Fed's year-end target as the participation rate declined to 61.6. Hourly earnings rose 0.6% and are up 4.3% in the year through August. The Fed will most likely wait to see the next employment report before beginning tapering.\nThe Eurozone economy has finally exceeded pre-covid levels, with most of the 20 indices that we monitor accelerating in recent weeks as cases/deaths have declined meaningfully. Shortages and supply line issues have hampered production while increasing inflationary pressures and won't ease until mid-2022. Energy costs are a real problem and may penalize growth next year. Unfortunately, OPEC opted against a big output boost lifting production by only 400,000 barrels/day, which will not be enough to limit further price increases, especially if we have a cold winter. And natural gas prices have gone through the roof, which will crimp consumer spending and hurt corporate operating margins.\nThe global economy is improving as the number of covid cases, and deaths have peaked. Growth would even be more robust if not for shortages and supply line issues, but that will reverse as we move through 2022.\nInvestment Conclusions\nThursday, there was a massive sigh of relief when Congress agreed to extend the debt limit two months, ending the stalemate. We expect the Dems to coalesce around a roughly $2 trillion social infrastructure bill that will permit passage of the much-needed $1 trillion traditional infrastructure bill. What is a government? Fiscal policy will remain stimulative for years to come.\nThen we have a monetary policy. We expect the Fed to remain accommodative for a few more years. We do expect tapering to begin before year-end if the November employment report improves from the last one, but we do not see a rate hike until 2023, and even then, the \"real\" funds' rate will be negative, which is not restrictive at all.\nShortages and supply line issues have played havoc on production and profitability for many industries/companies around the world in 2021, but this will reverse as we move through 2022, creating opportunities for investors willing to look over the valley.\nThe bottom line is that we could have a great year in 2022 if our government could get its act together. The key remains keeping the coronavirus out of the picture, so we must vaccinate all the unvaccinated.\nWhile we have not seen many changes in our portfolio over the last few months, we have concentrated on the producers that will benefit from a robust global economy and tech companies benefitting from the digitalization boom. We recently added some financials and energy companies as we expect the yield curve to steepen more than previously anticipated. Higher energy prices are immediately ahead as demand outstrips supply. Next year, the big story will be the significant increase in dividends and buybacks well above the historical trend.","news_type":1},"isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823582118,"gmtCreate":1633649377190,"gmtModify":1633649377382,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Hopefully more bullish run tonight.","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Hopefully more bullish run tonight.","text":"$Apple(AAPL)$Hopefully more bullish run tonight.","images":[{"img":"https://static.tigerbbs.com/301856a045b0599f0b01bd045eab71b3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823582118","isVote":1,"tweetType":1,"viewCount":475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":864685023,"gmtCreate":1633097856622,"gmtModify":1633097856762,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Is this why...for BioNTech investors = Negative news?","listText":"Is this why...for BioNTech investors = Negative news?","text":"Is this why...for BioNTech investors = Negative news?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864685023","repostId":"2172968435","repostType":4,"repost":{"id":"2172968435","pubTimestamp":1633097043,"share":"https://www.laohu8.com/m/news/2172968435?lang=&edition=full","pubTime":"2021-10-01 22:04","market":"us","language":"en","title":"Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News","url":"https://stock-news.laohu8.com/highlight/detail?id=2172968435","media":"Investing.com","summary":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in pre","content":"<p>By Geoffrey Smith</p>\n<p>Investing.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.</p>\n<p>By (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.&nbsp; Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.</p>\n<p>Merck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.</p>\n<p>The study was stopped early, as is often the case when an experimental drug shows signs of efficacy.</p>\n<p>Scientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.</p>\n<p>Related Articles</p>\n<p>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</p>\n<p>Stocks under pressure as euro zone inflation hits 13-year high</p>\n<p>Merck's COVID-19 pill cuts risk of death, hospitalization by 50% in study</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NWS":"新闻集团","MRNA":"Moderna, Inc.","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/moderna-biontech-pfizer-fall-merck-085413419.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172968435","content_text":"By Geoffrey Smith\nInvesting.com -- Shares in the makers of Covid-19 vaccines all fell sharply in premarket trading on Friday on expectations that Merck's experimental pill for treating the disease could radically undercut future demand for their drugs.\nBy (8:45 AM ET 1345 GMT), Moderna (NASDAQ:MRNA) stock was down 4.9%, while BioNTech stock was down 5.3% and Pfizer (NYSE:PFE) stock was down 1.9%.  Pfizer has traditionally been the least price-sensitive to vaccine news because it has many other revenue sources, whereas the other two are, for the present at least, pure plays on Covid-19 treatments.\nMerck (NYSE:MRK) had said earlier that an early-stage trial of its experimental pill had led to clear reductions in hospitalizations among the sample group, all of whom had taken it after developing moderate symptoms of Covid-19.\nThe study was stopped early, as is often the case when an experimental drug shows signs of efficacy.\nScientists have searched feverishly for a Covid-19 remedy that can be manufactured, distributed and administered at massive scale without arousing the suspicions and mistrust that often accompany new vaccines. Such a pill could transform the vaccination status of many poorer countries, where Covid-19 is still spreading more or less unimpeded due to the lack of vaccines in the developing world.\nRelated Articles\nModerna, BioNTech, Pfizer Fall on Merck Covid-19 Pill News\nStocks under pressure as euro zone inflation hits 13-year high\nMerck's COVID-19 pill cuts risk of death, hospitalization by 50% in study","news_type":1},"isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864152478,"gmtCreate":1633077746370,"gmtModify":1633077746546,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>It's like I see no hope at all...manage to average down but the price plummet even further today.","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>It's like I see no hope at all...manage to average down but the price plummet even further today.","text":"$BioNTech SE(BNTX)$It's like I see no hope at all...manage to average down but the price plummet even further today.","images":[{"img":"https://static.tigerbbs.com/27332c301aa7b18209f2e41ac46cd4ce","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864152478","isVote":1,"tweetType":1,"viewCount":465,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":862331592,"gmtCreate":1632836859315,"gmtModify":1632836859416,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>time to faint???","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>time to faint???","text":"$BioNTech SE(BNTX)$time to faint???","images":[{"img":"https://static.tigerbbs.com/b1b5ef580293b62713f8ef5516808ee5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/862331592","isVote":1,"tweetType":1,"viewCount":1054,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861423870,"gmtCreate":1632532705290,"gmtModify":1632710797285,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Why is the stock price always disappointing, past its&nbsp;heyday? Holding on is so draining...&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Why is the stock price always disappointing, past its&nbsp;heyday? Holding on is so draining...&nbsp;","text":"$BioNTech SE(BNTX)$Why is the stock price always disappointing, past its heyday? Holding on is so draining...","images":[{"img":"https://static.tigerbbs.com/a4a44486163cb336e20188132c1bb559","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861423870","isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":869739702,"gmtCreate":1632320972306,"gmtModify":1632801246242,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Happy!","listText":"Happy!","text":"Happy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/869739702","repostId":"1143821004","repostType":4,"repost":{"id":"1143821004","pubTimestamp":1632320072,"share":"https://www.laohu8.com/m/news/1143821004?lang=&edition=full","pubTime":"2021-09-22 22:14","market":"us","language":"en","title":"Apple sees 5M iPhone 13 pre-orders in China--report","url":"https://stock-news.laohu8.com/highlight/detail?id=1143821004","media":"seekingalpha","summary":"Barely $one$ week after unveiling the iPhone 13, $Apple$ is already seeing strong initial demand for its flagship product coming out of China.TheSouth China Morning $Post$reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple  Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company $JD.com$took more than 3 million","content":"<p>Barely <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after unveiling the iPhone 13, <a href=\"https://laohu8.com/S/AAPL\">Apple</a>&nbsp;is already seeing strong initial demand for its flagship product coming out of China.</p>\n<p>The<i>South China Morning <a href=\"https://laohu8.com/S/POST\">Post</a></i>reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. The<i>Post</i>said that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company <a href=\"https://laohu8.com/S/JD\">JD.com</a>(NASDAQ:JD)took more than 3 million iPhone 13 pre-order</p>\n<p>The four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.</p>\n<p>Earlier this week, <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.</p>\n<p>Apple gained over 1% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ac2063b03f2196c3d0a449ab604bd718\" tg-width=\"972\" tg-height=\"561\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple sees 5M iPhone 13 pre-orders in China--report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple sees 5M iPhone 13 pre-orders in China--report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that ...</p>\n\n<a href=\"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1143821004","content_text":"Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company JD.com(NASDAQ:JD)took more than 3 million iPhone 13 pre-order\nThe four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.\nEarlier this week, Bank of America analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.\nApple gained over 1% in early trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860812520,"gmtCreate":1632151534160,"gmtModify":1632802473186,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","text":"$Apple(AAPL)$Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","images":[{"img":"https://static.tigerbbs.com/b0af89bb1574b432e8444f3f77f33d8f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860812520","isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":818774678,"gmtCreate":1630453360694,"gmtModify":1631891607506,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","listText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","text":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/818774678","repostId":"818716571","repostType":1,"repost":{"id":818716571,"gmtCreate":1630449630993,"gmtModify":1631883797747,"author":{"id":"3552874562834581","authorId":"3552874562834581","authorIdStr":"3552874562834581","name":"Kel1","avatar":"https://static.tigerbbs.com/85967b7114ebaa24185158560185f10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3552874562834581"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","text":"$BioNTech SE(BNTX)$Will this recover?","images":[{"img":"https://static.tigerbbs.com/05a1cc87ba51e480f080e8ee03874f6d","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818716571","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811408639,"gmtCreate":1630334341921,"gmtModify":1704958704461,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? 😍","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? 😍","text":"$Apple(AAPL)$Could it go up to $159?/$160 mark? 😍","images":[{"img":"https://static.tigerbbs.com/4598427e97b0516704e776ad6ac92d5c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/811408639","isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":835555011,"gmtCreate":1629728460633,"gmtModify":1631891607533,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Hopefully it will rise to about its pre-glory price of $480+?","listText":"Hopefully it will rise to about its pre-glory price of $480+?","text":"Hopefully it will rise to about its pre-glory price of $480+?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835555011","repostId":"1189910879","repostType":4,"isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839819716,"gmtCreate":1629138426235,"gmtModify":1631891607546,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>will it go to $160? To hold or sell?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>will it go to $160? To hold or sell?","text":"$Apple(AAPL)$will it go to $160? To hold or sell?","images":[{"img":"https://static.tigerbbs.com/d28cd1e227e2939062a78ffd74a079f3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839819716","isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":839321095,"gmtCreate":1629123032917,"gmtModify":1631883798019,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","text":"$BioNTech SE(BNTX)$what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","images":[{"img":"https://static.tigerbbs.com/f48fe970fb82f2b25a061d030b7565cb","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":78,"commentSize":27,"repostSize":1,"link":"https://laohu8.com/post/839321095","isVote":1,"tweetType":1,"viewCount":3882,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"262190804341046","authorId":"262190804341046","authorIdStr":"262190804341046","name":"Jason1205","avatar":"https://static.tigerbbs.com/a22c3af3bb938bf74c151660df1d68dd","crmLevel":9,"crmLevelSwitch":0,"idStr":"262190804341046"},"content":"because of Afghanistan?","text":"because of Afghanistan?","html":"because of Afghanistan?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":897013387,"gmtCreate":1628862601349,"gmtModify":1631891607556,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","listText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","text":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/897013387","repostId":"1141206470","repostType":4,"repost":{"id":"1141206470","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628861824,"share":"https://www.laohu8.com/m/news/1141206470?lang=&edition=full","pubTime":"2021-08-13 21:37","market":"us","language":"en","title":"BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1141206470","media":"Tiger Newspress","summary":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster ","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141206470","content_text":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.\nBioNTech was up 3% and Moderna gained 3%, while Pfizer , which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.\n\nLate on Thursday, the U.S. Food and Drug Administration authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.\nPfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.\nGoing forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":839321095,"gmtCreate":1629123032917,"gmtModify":1631883798019,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","text":"$BioNTech SE(BNTX)$what is happening? Why was it doing well last week and today opening mkt and it sink so bad?","images":[{"img":"https://static.tigerbbs.com/f48fe970fb82f2b25a061d030b7565cb","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":78,"commentSize":27,"repostSize":1,"link":"https://laohu8.com/post/839321095","isVote":1,"tweetType":1,"viewCount":3882,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"262190804341046","authorId":"262190804341046","authorIdStr":"262190804341046","name":"Jason1205","avatar":"https://static.tigerbbs.com/a22c3af3bb938bf74c151660df1d68dd","crmLevel":9,"crmLevelSwitch":0,"idStr":"262190804341046"},"content":"because of Afghanistan?","text":"because of Afghanistan?","html":"because of Afghanistan?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":808478047,"gmtCreate":1627608292589,"gmtModify":1631886148830,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>OMG! SOMEONE PLEASE TELL me this stock will soar soon and not plummet further...to sell or not to sell now?","listText":"<a href=\"https://laohu8.com/S/PINS\">$Pinterest, Inc.(PINS)$</a>OMG! SOMEONE PLEASE TELL me this stock will soar soon and not plummet further...to sell or not to sell now?","text":"$Pinterest, Inc.(PINS)$OMG! SOMEONE PLEASE TELL me this stock will soar soon and not plummet further...to sell or not to sell now?","images":[{"img":"https://static.tigerbbs.com/d3f4c62fda66a6d444a2407e7ba7c2c7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/808478047","isVote":1,"tweetType":1,"viewCount":1527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":862331592,"gmtCreate":1632836859315,"gmtModify":1632836859416,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>time to faint???","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>time to faint???","text":"$BioNTech SE(BNTX)$time to faint???","images":[{"img":"https://static.tigerbbs.com/b1b5ef580293b62713f8ef5516808ee5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/862331592","isVote":1,"tweetType":1,"viewCount":1054,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":870746623,"gmtCreate":1636655711171,"gmtModify":1636655711386,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously? Why is this tanking when more vaccines are needed now for 3rd booster shots as well as for 5 - 11yo? Frustrating...😑","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Seriously? Why is this tanking when more vaccines are needed now for 3rd booster shots as well as for 5 - 11yo? Frustrating...😑","text":"$BioNTech SE(BNTX)$Seriously? Why is this tanking when more vaccines are needed now for 3rd booster shots as well as for 5 - 11yo? Frustrating...😑","images":[{"img":"https://static.tigerbbs.com/7023799f8e65f048e38dc8f783b6a876","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/870746623","isVote":1,"tweetType":1,"viewCount":982,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":894097920,"gmtCreate":1628776934260,"gmtModify":1631891607569,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Fantastic positive&nbsp; news! Keeping fingers crossed!","listText":"Fantastic positive&nbsp; news! Keeping fingers crossed!","text":"Fantastic positive news! Keeping fingers crossed!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894097920","repostId":"2158325931","repostType":4,"repost":{"id":"2158325931","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://www.laohu8.com/m/news/2158325931?lang=&edition=full","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801200884,"gmtCreate":1627517023748,"gmtModify":1631884033764,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...any chance of a lift-up?&nbsp;","listText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...any chance of a lift-up?&nbsp;","text":"$Lemonade, Inc.(LMND)$sigh...any chance of a lift-up?","images":[{"img":"https://static.tigerbbs.com/74964a2fe535cbfb8cc997e1bd52365d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/801200884","isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":155359063,"gmtCreate":1625379288252,"gmtModify":1633941075727,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Good article, thanks!","listText":"Good article, thanks!","text":"Good article, thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/155359063","repostId":"1160702483","repostType":4,"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860812520,"gmtCreate":1632151534160,"gmtModify":1632802473186,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","text":"$Apple(AAPL)$Just dipped to my buying price...is this gonna stay like that for the next few days...or weeks...?","images":[{"img":"https://static.tigerbbs.com/b0af89bb1574b432e8444f3f77f33d8f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860812520","isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":811408639,"gmtCreate":1630334341921,"gmtModify":1704958704461,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? 😍","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Could it go up to $159?/$160 mark? 😍","text":"$Apple(AAPL)$Could it go up to $159?/$160 mark? 😍","images":[{"img":"https://static.tigerbbs.com/4598427e97b0516704e776ad6ac92d5c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/811408639","isVote":1,"tweetType":1,"viewCount":316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":846771824,"gmtCreate":1636118254704,"gmtModify":1636118931968,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Wth...","listText":"Wth...","text":"Wth...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846771824","repostId":"1196545101","repostType":2,"repost":{"id":"1196545101","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636114848,"share":"https://www.laohu8.com/m/news/1196545101?lang=&edition=full","pubTime":"2021-11-05 20:20","market":"us","language":"en","title":"Vaccine stocks slipped after Pfizer announced its good news","url":"https://stock-news.laohu8.com/highlight/detail?id=1196545101","media":"Tiger Newspress","summary":"Vaccine stocks slipped after Pfizer announced his good news.Pfizer said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.BioNTech SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly and AstraZeneca fell between 1% and 11%.Whlie Pfizer surged 12% in premarket trading.","content":"<p>Vaccine stocks slipped after Pfizer announced his good news.Pfizer&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.</p>\n<p>BioNTech&nbsp;SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly&nbsp;and&nbsp;AstraZeneca&nbsp;fell&nbsp;between 1% and 11%.Whlie&nbsp;Pfizer&nbsp;surged&nbsp;12%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8a70ae8e53167b1da5670c9bd985e930\" tg-width=\"402\" tg-height=\"664\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks slipped after Pfizer announced its good news</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks slipped after Pfizer announced its good news\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks slipped after Pfizer announced his good news.Pfizer&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.</p>\n<p>BioNTech&nbsp;SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly&nbsp;and&nbsp;AstraZeneca&nbsp;fell&nbsp;between 1% and 11%.Whlie&nbsp;Pfizer&nbsp;surged&nbsp;12%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/8a70ae8e53167b1da5670c9bd985e930\" tg-width=\"402\" tg-height=\"664\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","MRNA":"Moderna, Inc.","PFE":"辉瑞","GILD":"吉利德科学","INO":"伊诺维奥制药","VIR":"Vir Biotechnology, Inc.","LLY":"礼来","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","REGN":"再生元制药公司","AZN":"阿斯利康"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196545101","content_text":"Vaccine stocks slipped after Pfizer announced his good news.Pfizer said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%.\nBioNTech SE,Moderna,Novavax,Merck,Regeneron Pharmaceuticals,Vir Biotechnology,Inovio Pharmaceuticals,Gilead Sciences,Eli Lilly and AstraZeneca fell between 1% and 11%.Whlie Pfizer surged 12% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825988159,"gmtCreate":1634190293162,"gmtModify":1634190293162,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"What about vaccine&nbsp;stocks...they are a little worrisome now with its constant yoyo prices?","listText":"What about vaccine&nbsp;stocks...they are a little worrisome now with its constant yoyo prices?","text":"What about vaccine stocks...they are a little worrisome now with its constant yoyo prices?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825988159","repostId":"1111412750","repostType":4,"repost":{"id":"1111412750","pubTimestamp":1634182832,"share":"https://www.laohu8.com/m/news/1111412750?lang=&edition=full","pubTime":"2021-10-14 11:40","market":"us","language":"en","title":"Buying The Dip Is Dead","url":"https://stock-news.laohu8.com/highlight/detail?id=1111412750","media":"seekingalpha","summary":"Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical rea","content":"<p>Summary</p>\n<ul>\n <li>Buying the dip died when the volatility sellers failed to show up.</li>\n <li>There's a mechanical reason why the market has not \"bounced back.\"</li>\n <li>That mechanical reason has broken down due to fundamental shifts.</li>\n</ul>\n<p>The market has been melting, and that \"buy the dip\" mentality seems to be in trouble. There's an excellent reason for why buying the dip hasn't worked, and probably why it won't work this time around either. All you have to do is look at the VIX and the SKEW indexes to understand why.</p>\n<p>Falling volatility has been a lynchpin of propping up the market every time it falters since the COVID low. Every time the market sank, the VIX would spike higher. Then, a swarm of traders would come in looking to short volatility, which would send the VIX lower, pushing the S&amp;P 500 higher. However, that component of the market appears to be gone. The VIX has been steadily rising since June, with higher lows. More recently, the VIX hasn't been able to get below 18, and each drop in the S&amp;P 500 has seen lower highs.</p>\n<p><img src=\"https://static.tigerbbs.com/7d40186560f397cc6ebdc4e85ba18725\" tg-width=\"640\" tg-height=\"397\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Additionally, the SKEW index has cratered in recent weeks. It's because traders that have been betting on volatility falling have likely been shorting at-the-money forms of it, and to hedge those positions, they have been buying out-of-money forms. It's why the SKEW index reached record highs in June as the VIX hit its lows.</p>\n<p>The SKEW index wasn't rising into June 2021 because traders were trying to hedge against tail risk or an unforeseen event. The SKEW index was rising as a hedge against short volatility positions.</p>\n<p>If volatility sellers do not return to this market, then a big piece of why the market always has been able to bounce back so quickly on every dip will be gone. Buying the dip will simply not work.</p>\n<p><img src=\"https://static.tigerbbs.com/d92c33e67c289d5c9d1e8d0d6ec74b5d\" tg-width=\"640\" tg-height=\"397\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>But with QE likely on its way out, financial conditions are likely to tighten as a result. It seems that volatility sellers have gone missing for a good reason. If that's the case, the considerable risk in the market isn't going to be the fear of missing out. The substantial risk is a meltdown, not all that&nbsp;dissimilar to that of 2018, which I have noted on several occasions many of the same similarities of today to back then.</p>\n<p>The dollar index may be a big piece of that. It has been surging higher, and that the S&amp;P 500 has been trading precisely the opposite to the dollar's move. When the dollar has been strengthening, the S&amp;P 500 has been falling and vice versa. The&nbsp;dollar is telling us that tapering&nbsp;is coming and very soon. The stock market knows what this means too, and it isn't good for stocks.</p>\n<p>The two-year Treasury rate has also been creeping higher and now stands at more than 35 bps. The two-year most likely needs to rise much more if the Fed is tapering. By the time the QE taper ended in October 2014, the two-year was around 50 to 60 bps. That means the&nbsp;two-year&nbsp;now has further to climb as this process commences potentially as soon as the November FOMC meeting.</p>\n<p>Despite the stronger dollar, the 10-year has been falling, and that's because the market is picking up on what I have been telling you for months. Growth rates here in the US and around the globe have been slowing and are now near stall speed. They have gotten so slow here in the US that the Atlanta Fed GDPNow is now projecting just a 1.3% third quarter growth rate, an enormous drop from the second-quarter reading of 6.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/ce210603773584da38e4fbf054f31ba9\" tg-width=\"640\" tg-height=\"480\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The market knows that a strong dollar in regular times exports inflationary forces aboard in countries that buy commodities, finances debt, or conduct business in dollars. It's a global growth killer. On top of that, rising prices for things like energy are already likely to slow growth, and now with the dollar rising, it makes the problem even more prominent. It is driving the rates on the long-end of the curve lower and flattening the yield curve.</p>\n<p>This time is different from previous pullbacks. This is why this time the pullback is only in its early phases. Earnings estimates have started to come down, and they are likely to come down further because if one thing is crystal clear, GDP growth expectations were way off base, and means that it is highly likely that&nbsp;earnings estimates&nbsp;are way off base, which means earnings growth rates will be heading lower or top of what they have declined.</p>\n<p><img src=\"https://static.tigerbbs.com/b784f4142c7b91a6c36b4c8d263db047\" tg-width=\"640\" tg-height=\"480\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>It's just a matter of when the stock market realizes that a Fed tapering event will push the dollar index even higher at the worst possible time resulting in a massive global growth scare. Perhaps the biggest reason why the volatility sellers have left the building.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buying The Dip Is Dead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuying The Dip Is Dead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 11:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4459696-buying-the-dip-is-dead><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical reason why the market has not \"bounced back.\"\nThat mechanical reason has broken down due to fundamental...</p>\n\n<a href=\"https://seekingalpha.com/article/4459696-buying-the-dip-is-dead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://seekingalpha.com/article/4459696-buying-the-dip-is-dead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111412750","content_text":"Summary\n\nBuying the dip died when the volatility sellers failed to show up.\nThere's a mechanical reason why the market has not \"bounced back.\"\nThat mechanical reason has broken down due to fundamental shifts.\n\nThe market has been melting, and that \"buy the dip\" mentality seems to be in trouble. There's an excellent reason for why buying the dip hasn't worked, and probably why it won't work this time around either. All you have to do is look at the VIX and the SKEW indexes to understand why.\nFalling volatility has been a lynchpin of propping up the market every time it falters since the COVID low. Every time the market sank, the VIX would spike higher. Then, a swarm of traders would come in looking to short volatility, which would send the VIX lower, pushing the S&P 500 higher. However, that component of the market appears to be gone. The VIX has been steadily rising since June, with higher lows. More recently, the VIX hasn't been able to get below 18, and each drop in the S&P 500 has seen lower highs.\n\nAdditionally, the SKEW index has cratered in recent weeks. It's because traders that have been betting on volatility falling have likely been shorting at-the-money forms of it, and to hedge those positions, they have been buying out-of-money forms. It's why the SKEW index reached record highs in June as the VIX hit its lows.\nThe SKEW index wasn't rising into June 2021 because traders were trying to hedge against tail risk or an unforeseen event. The SKEW index was rising as a hedge against short volatility positions.\nIf volatility sellers do not return to this market, then a big piece of why the market always has been able to bounce back so quickly on every dip will be gone. Buying the dip will simply not work.\n\nBut with QE likely on its way out, financial conditions are likely to tighten as a result. It seems that volatility sellers have gone missing for a good reason. If that's the case, the considerable risk in the market isn't going to be the fear of missing out. The substantial risk is a meltdown, not all that dissimilar to that of 2018, which I have noted on several occasions many of the same similarities of today to back then.\nThe dollar index may be a big piece of that. It has been surging higher, and that the S&P 500 has been trading precisely the opposite to the dollar's move. When the dollar has been strengthening, the S&P 500 has been falling and vice versa. The dollar is telling us that tapering is coming and very soon. The stock market knows what this means too, and it isn't good for stocks.\nThe two-year Treasury rate has also been creeping higher and now stands at more than 35 bps. The two-year most likely needs to rise much more if the Fed is tapering. By the time the QE taper ended in October 2014, the two-year was around 50 to 60 bps. That means the two-year now has further to climb as this process commences potentially as soon as the November FOMC meeting.\nDespite the stronger dollar, the 10-year has been falling, and that's because the market is picking up on what I have been telling you for months. Growth rates here in the US and around the globe have been slowing and are now near stall speed. They have gotten so slow here in the US that the Atlanta Fed GDPNow is now projecting just a 1.3% third quarter growth rate, an enormous drop from the second-quarter reading of 6.7%.\n\nThe market knows that a strong dollar in regular times exports inflationary forces aboard in countries that buy commodities, finances debt, or conduct business in dollars. It's a global growth killer. On top of that, rising prices for things like energy are already likely to slow growth, and now with the dollar rising, it makes the problem even more prominent. It is driving the rates on the long-end of the curve lower and flattening the yield curve.\nThis time is different from previous pullbacks. This is why this time the pullback is only in its early phases. Earnings estimates have started to come down, and they are likely to come down further because if one thing is crystal clear, GDP growth expectations were way off base, and means that it is highly likely that earnings estimates are way off base, which means earnings growth rates will be heading lower or top of what they have declined.\n\nIt's just a matter of when the stock market realizes that a Fed tapering event will push the dollar index even higher at the worst possible time resulting in a massive global growth scare. Perhaps the biggest reason why the volatility sellers have left the building.","news_type":1},"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869739702,"gmtCreate":1632320972306,"gmtModify":1632801246242,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Happy!","listText":"Happy!","text":"Happy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/869739702","repostId":"1143821004","repostType":4,"repost":{"id":"1143821004","pubTimestamp":1632320072,"share":"https://www.laohu8.com/m/news/1143821004?lang=&edition=full","pubTime":"2021-09-22 22:14","market":"us","language":"en","title":"Apple sees 5M iPhone 13 pre-orders in China--report","url":"https://stock-news.laohu8.com/highlight/detail?id=1143821004","media":"seekingalpha","summary":"Barely $one$ week after unveiling the iPhone 13, $Apple$ is already seeing strong initial demand for its flagship product coming out of China.TheSouth China Morning $Post$reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple  Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company $JD.com$took more than 3 million","content":"<p>Barely <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after unveiling the iPhone 13, <a href=\"https://laohu8.com/S/AAPL\">Apple</a>&nbsp;is already seeing strong initial demand for its flagship product coming out of China.</p>\n<p>The<i>South China Morning <a href=\"https://laohu8.com/S/POST\">Post</a></i>reported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. The<i>Post</i>said that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company <a href=\"https://laohu8.com/S/JD\">JD.com</a>(NASDAQ:JD)took more than 3 million iPhone 13 pre-order</p>\n<p>The four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.</p>\n<p>Earlier this week, <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.</p>\n<p>Apple gained over 1% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ac2063b03f2196c3d0a449ab604bd718\" tg-width=\"972\" tg-height=\"561\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple sees 5M iPhone 13 pre-orders in China--report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple sees 5M iPhone 13 pre-orders in China--report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that ...</p>\n\n<a href=\"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/news/3742266-apple-sees-5m-iphone-pre-orders-in-china-report","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1143821004","content_text":"Barely one week after unveiling the iPhone 13, Apple is already seeing strong initial demand for its flagship product coming out of China.\nTheSouth China Morning Postreported Wednesday that approximately 5 million pre-orders of the iPhone 13 have been made in the eight days since Apple (AAPL) Chief Executive Tim Cook showed of the smartphone. ThePostsaid that online traffic was so heavy that Apple's China site slowed to a crawl, and that Chinese e-commerce company JD.com(NASDAQ:JD)took more than 3 million iPhone 13 pre-order\nThe four new iPhones--iPhone 13, iPhone 13 Mini, iPhone 13 Pro and iPhone 13 Pro Max--officially go on sale on September 24.\nEarlier this week, Bank of America analyst Wamsi Mohan said in a research report that initial retail checks showediPhone 13 pre-orders outpacing those of the iPhone 12 a year ago.\nApple gained over 1% in early trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803515657,"gmtCreate":1627447666379,"gmtModify":1631884033765,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>Are we fools to believe we did not buy lemons? 😵","listText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>Are we fools to believe we did not buy lemons? 😵","text":"$Lemonade, Inc.(LMND)$Are we fools to believe we did not buy lemons? 😵","images":[{"img":"https://static.tigerbbs.com/f76495f183af361c81cae2ed09407afa","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803515657","isVote":1,"tweetType":1,"viewCount":138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":600451700,"gmtCreate":1638191764950,"gmtModify":1638191765142,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"It's all good news to us investors.&nbsp;","listText":"It's all good news to us investors.&nbsp;","text":"It's all good news to us investors.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600451700","repostId":"1173904581","repostType":4,"repost":{"id":"1173904581","pubTimestamp":1638186226,"share":"https://www.laohu8.com/m/news/1173904581?lang=&edition=full","pubTime":"2021-11-29 19:43","market":"us","language":"en","title":"BioNTech Is Working On an Omicron Version of Its Covid Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1173904581","media":"Bloomberg","summary":"BioNTech SE is working to adapt its Covid-19 vaccine to address the omicron variant and expects to h","content":"<p>BioNTech SE&nbsp;is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary.</p>\n<p>BioNTech SE&nbsp;stock&nbsp;jumped&nbsp;5%&nbsp;in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/df27de31843e0340df06283dfd4547ae\" tg-width=\"850\" tg-height=\"618\" width=\"100%\" height=\"auto\"></p>\n<p>The company has started development in order to move as quickly as possible, BioNTech said in a statement. The first steps of developing a new vaccine overlap with the&nbsp;research&nbsp;necessary in order to evaluate whether a new shot will be needed -- a process that began last Thursday as soon as&nbsp;news&nbsp;of the new variant began to spread around the world.</p>\n<p>The German biotech and its Covid vaccine partner&nbsp;Pfizer Inc.&nbsp;put plans into place months ago to ensure a new version of their shot could ship within 100 days if necessary. The omicron variant has raised concerns around the world, with countries implementing travel bans to buy time as researchers race to study whether it will evade vaccines and spread more rapidly. It will probably take weeks to understand the full impact of the variant, scientists have said.</p>\n<p>Moderna Inc., which makes another messenger-RNA vaccine for Covid, has begun a similar&nbsp;process&nbsp;of evaluation and development, should a new shot be necessary. Both companies have said it should become clear within weeks whether an adapted vaccine will be needed.</p>\n<p>Vaccinated people should still be protected, depending on how long ago they got their shots, and for now the best advice is to take one of the current Covid vaccines, Moderna Chief Medical Officer Paul Burton said on Sunday on the BBC’s “Andrew Marr Show.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Is Working On an Omicron Version of Its Covid Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Is Working On an Omicron Version of Its Covid Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 19:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-29/biontech-is-working-on-an-omicron-version-of-its-covid-shot?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech SE is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary.\nBioNTech SE stock jumped 5% in premarket ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-29/biontech-is-working-on-an-omicron-version-of-its-covid-shot?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-29/biontech-is-working-on-an-omicron-version-of-its-covid-shot?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173904581","content_text":"BioNTech SE is working to adapt its Covid-19 vaccine to address the omicron variant and expects to have a new version ready within 100 days if necessary.\nBioNTech SE stock jumped 5% in premarket trading.\n\nThe company has started development in order to move as quickly as possible, BioNTech said in a statement. The first steps of developing a new vaccine overlap with the research necessary in order to evaluate whether a new shot will be needed -- a process that began last Thursday as soon as news of the new variant began to spread around the world.\nThe German biotech and its Covid vaccine partner Pfizer Inc. put plans into place months ago to ensure a new version of their shot could ship within 100 days if necessary. The omicron variant has raised concerns around the world, with countries implementing travel bans to buy time as researchers race to study whether it will evade vaccines and spread more rapidly. It will probably take weeks to understand the full impact of the variant, scientists have said.\nModerna Inc., which makes another messenger-RNA vaccine for Covid, has begun a similar process of evaluation and development, should a new shot be necessary. Both companies have said it should become clear within weeks whether an adapted vaccine will be needed.\nVaccinated people should still be protected, depending on how long ago they got their shots, and for now the best advice is to take one of the current Covid vaccines, Moderna Chief Medical Officer Paul Burton said on Sunday on the BBC’s “Andrew Marr Show.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":818774678,"gmtCreate":1630453360694,"gmtModify":1631891607506,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","listText":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","text":"Am in the same boat as you. Bought at $452, average down $392...and have an almost heart attack to see it drop to $329 now...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/818774678","repostId":"818716571","repostType":1,"repost":{"id":818716571,"gmtCreate":1630449630993,"gmtModify":1631883797747,"author":{"id":"3552874562834581","authorId":"3552874562834581","authorIdStr":"3552874562834581","name":"Kel1","avatar":"https://static.tigerbbs.com/85967b7114ebaa24185158560185f10b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3552874562834581"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Will this recover?","text":"$BioNTech SE(BNTX)$Will this recover?","images":[{"img":"https://static.tigerbbs.com/05a1cc87ba51e480f080e8ee03874f6d","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818716571","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144626311,"gmtCreate":1626282306633,"gmtModify":1631884033836,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...is there a chance price will recover? 😭","listText":"<a href=\"https://laohu8.com/S/LMND\">$Lemonade, Inc.(LMND)$</a>sigh...is there a chance price will recover? 😭","text":"$Lemonade, Inc.(LMND)$sigh...is there a chance price will recover? 😭","images":[{"img":"https://static.tigerbbs.com/497235e9b9d50221612d15e54678aa40","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/144626311","isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143091164,"gmtCreate":1625751779058,"gmtModify":1631891607618,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"No wonder...😭","listText":"No wonder...😭","text":"No wonder...😭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/143091164","repostId":"1143211463","repostType":4,"repost":{"id":"1143211463","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625751059,"share":"https://www.laohu8.com/m/news/1143211463?lang=&edition=full","pubTime":"2021-07-08 21:30","market":"us","language":"en","title":"Dow drops 400 points amid global economic recovery concerns, bond yields slide","url":"https://stock-news.laohu8.com/highlight/detail?id=1143211463","media":"Tiger Newspress","summary":"The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Cov","content":"<p>The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Covid-19. The losses came as Japandeclared a state of emergency in Tokyofor the upcoming Olympics and as countries deal with a rebound in cases because of Covid variants.</p>\n<p>The Dow Jones Industrial Average dropped about 400 points, or 1.1% with losses increasing throughout the overnight session. The S&amp;P 500 lost 1.25%. The Nasdaq 100 Composite fell 1.6%. Both the S&amp;P 500 and Nasdaq Composite closed at records in the prior session because of gains from tech shares.</p>\n<p>The Labor Department'slatest jobless claims datacame in unexpectedly higher at 373,000, signaling a slowdown in the the labor picture amid the Covid recovery. Economists expected to see 350,000 first-time applicants for unemployment benefits for the week ended July 3, according to Dow Jones.</p>\n<p>Premarket losses were led by companies that would benefit from a rapid economic comeback from the virus. Shares ofCarnivalandRoyal Caribbeaneach dropped more than 3%.American AirlinesandDelta Air Lineseach fell more than 2% in early trading.Boeingfell 2%.FordandNikewere also lower. RetailersLowe'sandHome Depotalso dipped in premarket trading.</p>\n<p>Chip stocks also fell on concerns about the pace of the global recovery.Micron,NVIDIA,Qualcomm,IntelandApplied Materialsalso ticked lower in the premarket.</p>\n<p>\"The market has been in one of those 'Goldilocks' stretches when economic growth was accelerating while inflation and interest rates remained low.&nbsp;Increased Covid cases, particularly Delta Variants have caused concerns that the economic acceleration will slow,\" Timothy Lesko of Granite Investment Advisors told CNBC. \"A few weeks ago the porridge was too hot, now it seems it is too cold.&nbsp;With markets at all time highs and some valuations stretched there is little room for economic slowdown in this market.\"</p>\n<p>Investors rotated into the safety of Treasuries further on Thursday, pushing the yield on the10-year Treasurybelow 1.255% to the lowest since late February. Despite the recovering economy and fast inflation, the 10-year Treasury yield continues to decline. It was at 1.58% to start July and hit a 2021 high of 1.78% in March. Traders remain confused about the exact reasons for the rollover in yields, with many citing concern that the best of the economic recovery may be behind us.</p>\n<p>Bank of America,Wells Fargo,Goldman Sachsand other financial shares declined in premarket trading as their profitability outlook dimmed with lower rates.JPMorgan ChaseandPNC Financialwere also lower.</p>\n<p>\"Nothing suggests the near slump in yields is over,\" wrote Christopher Harvey, head of equity strategy at Wells Fargo, in a note Thursday. \"A sharp drop below 1.25% could cause equity PMs to believe that something is wrong or broken. As a result, we see a growing possibility of a 5% selloff in equities before earnings season.\"</p>\n<p>Harvey noted he believes the buying in bonds is more technical in nature and not due to macroeconomic factors.</p>\n<p>Spectatorscould be banned from the Olympic games, according to a report following the state of emergency declaration for Tokyo by Japan.</p>\n<p>Meanwhile the global Covid death toll continued to advance,exceeding 4 million on late Wednesday, as countries including India battle more transmissible variants.</p>\n<p>TheCboe Volatility index, or 'VIX,' surged above the key 20 level Thursday morning, perhaps signaling a period of greater volatility ahead.</p>\n<p>\"The 40 basis point decline in the yield on the benchmark 10-year Treasury note since late-March suggests that the global grab for yield remains a potent force, despite the Fed's desire to let the economy run hot,\" Steven Ricchiuto, U.S. chief economist at Mizuho Securities, wrote in a note this week.</p>\n<p>\"A stronger currency, increased virus concerns oversea, and the associated demand for long-term Treasury notes and bonds implies reduced inflation expectations and increased risk of importing global deflation,\" he added.</p>\n<p>So-called meme stocks took big hits on Thursday as the sell-off caused investors to flee stocks likeAMCandGameStopthat had been boosted by speculative trading by retail traders chatting on Reddit.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow drops 400 points amid global economic recovery concerns, bond yields slide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow drops 400 points amid global economic recovery concerns, bond yields slide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-08 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Covid-19. The losses came as Japandeclared a state of emergency in Tokyofor the upcoming Olympics and as countries deal with a rebound in cases because of Covid variants.</p>\n<p>The Dow Jones Industrial Average dropped about 400 points, or 1.1% with losses increasing throughout the overnight session. The S&amp;P 500 lost 1.25%. The Nasdaq 100 Composite fell 1.6%. Both the S&amp;P 500 and Nasdaq Composite closed at records in the prior session because of gains from tech shares.</p>\n<p>The Labor Department'slatest jobless claims datacame in unexpectedly higher at 373,000, signaling a slowdown in the the labor picture amid the Covid recovery. Economists expected to see 350,000 first-time applicants for unemployment benefits for the week ended July 3, according to Dow Jones.</p>\n<p>Premarket losses were led by companies that would benefit from a rapid economic comeback from the virus. Shares ofCarnivalandRoyal Caribbeaneach dropped more than 3%.American AirlinesandDelta Air Lineseach fell more than 2% in early trading.Boeingfell 2%.FordandNikewere also lower. RetailersLowe'sandHome Depotalso dipped in premarket trading.</p>\n<p>Chip stocks also fell on concerns about the pace of the global recovery.Micron,NVIDIA,Qualcomm,IntelandApplied Materialsalso ticked lower in the premarket.</p>\n<p>\"The market has been in one of those 'Goldilocks' stretches when economic growth was accelerating while inflation and interest rates remained low.&nbsp;Increased Covid cases, particularly Delta Variants have caused concerns that the economic acceleration will slow,\" Timothy Lesko of Granite Investment Advisors told CNBC. \"A few weeks ago the porridge was too hot, now it seems it is too cold.&nbsp;With markets at all time highs and some valuations stretched there is little room for economic slowdown in this market.\"</p>\n<p>Investors rotated into the safety of Treasuries further on Thursday, pushing the yield on the10-year Treasurybelow 1.255% to the lowest since late February. Despite the recovering economy and fast inflation, the 10-year Treasury yield continues to decline. It was at 1.58% to start July and hit a 2021 high of 1.78% in March. Traders remain confused about the exact reasons for the rollover in yields, with many citing concern that the best of the economic recovery may be behind us.</p>\n<p>Bank of America,Wells Fargo,Goldman Sachsand other financial shares declined in premarket trading as their profitability outlook dimmed with lower rates.JPMorgan ChaseandPNC Financialwere also lower.</p>\n<p>\"Nothing suggests the near slump in yields is over,\" wrote Christopher Harvey, head of equity strategy at Wells Fargo, in a note Thursday. \"A sharp drop below 1.25% could cause equity PMs to believe that something is wrong or broken. As a result, we see a growing possibility of a 5% selloff in equities before earnings season.\"</p>\n<p>Harvey noted he believes the buying in bonds is more technical in nature and not due to macroeconomic factors.</p>\n<p>Spectatorscould be banned from the Olympic games, according to a report following the state of emergency declaration for Tokyo by Japan.</p>\n<p>Meanwhile the global Covid death toll continued to advance,exceeding 4 million on late Wednesday, as countries including India battle more transmissible variants.</p>\n<p>TheCboe Volatility index, or 'VIX,' surged above the key 20 level Thursday morning, perhaps signaling a period of greater volatility ahead.</p>\n<p>\"The 40 basis point decline in the yield on the benchmark 10-year Treasury note since late-March suggests that the global grab for yield remains a potent force, despite the Fed's desire to let the economy run hot,\" Steven Ricchiuto, U.S. chief economist at Mizuho Securities, wrote in a note this week.</p>\n<p>\"A stronger currency, increased virus concerns oversea, and the associated demand for long-term Treasury notes and bonds implies reduced inflation expectations and increased risk of importing global deflation,\" he added.</p>\n<p>So-called meme stocks took big hits on Thursday as the sell-off caused investors to flee stocks likeAMCandGameStopthat had been boosted by speculative trading by retail traders chatting on Reddit.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143211463","content_text":"The major U.S. stock indexes fell on Thursday on concern about the global economic comeback from Covid-19. The losses came as Japandeclared a state of emergency in Tokyofor the upcoming Olympics and as countries deal with a rebound in cases because of Covid variants.\nThe Dow Jones Industrial Average dropped about 400 points, or 1.1% with losses increasing throughout the overnight session. The S&P 500 lost 1.25%. The Nasdaq 100 Composite fell 1.6%. Both the S&P 500 and Nasdaq Composite closed at records in the prior session because of gains from tech shares.\nThe Labor Department'slatest jobless claims datacame in unexpectedly higher at 373,000, signaling a slowdown in the the labor picture amid the Covid recovery. Economists expected to see 350,000 first-time applicants for unemployment benefits for the week ended July 3, according to Dow Jones.\nPremarket losses were led by companies that would benefit from a rapid economic comeback from the virus. Shares ofCarnivalandRoyal Caribbeaneach dropped more than 3%.American AirlinesandDelta Air Lineseach fell more than 2% in early trading.Boeingfell 2%.FordandNikewere also lower. RetailersLowe'sandHome Depotalso dipped in premarket trading.\nChip stocks also fell on concerns about the pace of the global recovery.Micron,NVIDIA,Qualcomm,IntelandApplied Materialsalso ticked lower in the premarket.\n\"The market has been in one of those 'Goldilocks' stretches when economic growth was accelerating while inflation and interest rates remained low. Increased Covid cases, particularly Delta Variants have caused concerns that the economic acceleration will slow,\" Timothy Lesko of Granite Investment Advisors told CNBC. \"A few weeks ago the porridge was too hot, now it seems it is too cold. With markets at all time highs and some valuations stretched there is little room for economic slowdown in this market.\"\nInvestors rotated into the safety of Treasuries further on Thursday, pushing the yield on the10-year Treasurybelow 1.255% to the lowest since late February. Despite the recovering economy and fast inflation, the 10-year Treasury yield continues to decline. It was at 1.58% to start July and hit a 2021 high of 1.78% in March. Traders remain confused about the exact reasons for the rollover in yields, with many citing concern that the best of the economic recovery may be behind us.\nBank of America,Wells Fargo,Goldman Sachsand other financial shares declined in premarket trading as their profitability outlook dimmed with lower rates.JPMorgan ChaseandPNC Financialwere also lower.\n\"Nothing suggests the near slump in yields is over,\" wrote Christopher Harvey, head of equity strategy at Wells Fargo, in a note Thursday. \"A sharp drop below 1.25% could cause equity PMs to believe that something is wrong or broken. As a result, we see a growing possibility of a 5% selloff in equities before earnings season.\"\nHarvey noted he believes the buying in bonds is more technical in nature and not due to macroeconomic factors.\nSpectatorscould be banned from the Olympic games, according to a report following the state of emergency declaration for Tokyo by Japan.\nMeanwhile the global Covid death toll continued to advance,exceeding 4 million on late Wednesday, as countries including India battle more transmissible variants.\nTheCboe Volatility index, or 'VIX,' surged above the key 20 level Thursday morning, perhaps signaling a period of greater volatility ahead.\n\"The 40 basis point decline in the yield on the benchmark 10-year Treasury note since late-March suggests that the global grab for yield remains a potent force, despite the Fed's desire to let the economy run hot,\" Steven Ricchiuto, U.S. chief economist at Mizuho Securities, wrote in a note this week.\n\"A stronger currency, increased virus concerns oversea, and the associated demand for long-term Treasury notes and bonds implies reduced inflation expectations and increased risk of importing global deflation,\" he added.\nSo-called meme stocks took big hits on Thursday as the sell-off caused investors to flee stocks likeAMCandGameStopthat had been boosted by speculative trading by retail traders chatting on Reddit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156829894,"gmtCreate":1625212638318,"gmtModify":1631888920995,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>this is awesome! Fly soar up more please!!!","listText":"<a href=\"https://laohu8.com/S/JLB.SI\">$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$</a>this is awesome! Fly soar up more please!!!","text":"$GRAND VENTURE TECHNOLOGY LTD(JLB.SI)$this is awesome! Fly soar up more please!!!","images":[{"img":"https://static.tigerbbs.com/78b0585f0551ccd0cde04f644d3940c5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/156829894","isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":158082154,"gmtCreate":1625113838578,"gmtModify":1633944628286,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158082154","repostId":"1110936297","repostType":2,"repost":{"id":"1110936297","pubTimestamp":1625036047,"share":"https://www.laohu8.com/m/news/1110936297?lang=&edition=full","pubTime":"2021-06-30 14:54","market":"us","language":"en","title":"Apple: Act Quickly Before The Run To $172","url":"https://stock-news.laohu8.com/highlight/detail?id=1110936297","media":"seekingalpha","summary":"Apple faces many external threats from regulators in the developed world.But I see these as largely priced in, although they remain a threat longer term.Apple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.I have made it no secret that I’m a big fan of Apple. In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a big breakout. In this article, I want to ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Apple faces many external threats from regulators in the developed world.</li>\n <li>But I see these as largely priced in, although they remain a threat longer term.</li>\n <li>Apple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/219c4f41554f7e91be4c02cd87e3f8d6\" tg-width=\"1536\" tg-height=\"1024\"><span>fMing Yeung/Getty Images News</span></p>\n<p>I have made it no secret that I’m a big fan of&nbsp;<b>Apple</b>(AAPL). In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a&nbsp;big breakout. In this article, I want to update readers on the progress of that, as well as addressing some concerns that could be potentially bearish. But the spoiler alert is that I’m still very much in the camp of Apple setting up a breakout, and I think the company’s typical pre-earnings move is likely the catalyst to see that happen.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/37078c4ff01404a43176bb2e2555834d\" tg-width=\"640\" tg-height=\"615\"><span>Source: StockCharts</span></p>\n<p>To start, I’ve annotated the same ascending triangle formation I noted six weeks ago, because it is still very much in play. The stock is very near the top of the triangle today, so what happens when/if it gets to $136/$137 will determine if the breakout is imminent or if we need at least one more test of the rising trend line that forms the bottom of the triangle. Whether that occurs or not doesn’t change my outlook; only the timing of it.</p>\n<p>Ascending triangles measure upside targets on breakouts equal to the top and bottom of the widest part of the triangle. In this case, the top of the triangle is $137 and the bottom of the triangle, which was set in September of last year, was $102. That means that this triangle pattern has a measured price target – after the breakout – of $35 higher ($137 minus $102), and with the breakout point being $137 or so, that implies we canexpect Apple to hit $172, give or take. Now, that won’t happen immediately, of course, but that’s the kind of opportunity at hand here.</p>\n<p>What do you need to look for on a breakout? First, price action needs to decisively clear the breakout level of $137 and close above it. In addition, you want to see rising volume on the breakout – I’ve annotated declining volume in the triangle period, which is normal behavior – and you want to see rising momentum, we’ve got rising momentum today. So I’d expect a breakout to continue that, but these are the things you want to see on a breakout to ensure it has staying power.</p>\n<p>Finally, you’ll notice that I’ve added blue circles on the chart, and those represent the start of the ~4-week period prior to an earnings release. Apple has been<i>very</i>reliable in the past couple of years in terms of rallying into an earnings report, and I have no reason to think that will change. The gains are fairly large in most cases, with about half of them being in the double-digits, so this is a real catalyst for higher prices.</p>\n<p>The important thing to note is that we are about four weeks from the third quarter report, which typically takes place at the end of July. We are also at the top of the ascending triangle, which means that even a small pre-earnings run will likely result in a breakout, and that’s why I think the breakout is very near.</p>\n<p>To be clear, I’m reiterating my prior thesis that an ascending triangle breakout is coming; I just think we have a very clear catalyst now to make it sooner than later. I see the stock rallying into the earnings report, and if history is a guide, Apple will destroy expectations once again. In short, all is going to plan.</p>\n<p>The risk is that if Apple does break out of the triangle and earnings aren’t very good, the pattern could fail. That would negate my $172 price target, and we’d have to reassess. For now, the odds of that look low, and I’m still full steam ahead on the breakout coming pre-earnings.</p>\n<p><b>Why does Apple rally pre-earnings?</b></p>\n<p>To put it succinctly, Apple rallies pre-earnings because no matter how much analysts raise their targets going into the reports, Apple finds a way to beat them.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6233212bc10ea38f20e75d2ed0ab603e\" tg-width=\"640\" tg-height=\"284\"><span>Source:Seeking Alpha</span></p>\n<p>This is three years’ worth of data showing how Apple beats expectations, and by enormous margins in some cases. Apple is one of the largest and most-followed companies that has ever existed. So if any company should have an analyst community that knows how it will perform each quarter, it would be this one. However, its dominance in hardware and services revenue has proven too much for analysts over time to keep up with.</p>\n<p>Keep in mind a risk here is that if Apple does finally miss expectations, I have to imagine the stock will react extremely poorly. Thus, there is certainly risk in owning Apple through the earnings report, as with any other stock. But the company’s history of smashing expectations – particularly in the past year – means the odds of this are fairly low. Still, something to keep in mind from a risk perspective.</p>\n<p>In terms of a catalyst for rallying into the July report, Apple continues to see analysts scramble to keep up with its rising fortunes.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ebf56ca48e2364fd7314f9140bc3ab5c\" tg-width=\"640\" tg-height=\"286\"><span>Source:Seeking Alpha</span></p>\n<p>The sharp upward revisions that began last summer continue unabated, and Apple’s earnings trajectory remains very much intact. I detailed this in my last piece so I’m simply saying that nothing has changed on this front, and that’s a very good thing.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d2bd9aaadd1cc3a29d7b8e787296ab4b\" tg-width=\"454\" tg-height=\"110\"><span>Source:Seeking Alpha</span></p>\n<p>I think you’ll struggle to find a company with a better earnings revision schedule, as the past three months have seen 36 EPS revisions, and<i>100%</i>of them were upward. That shows just how strong Apple’s earnings trajectory is, as analysts scramble to meet Apple’s outstanding performances. I love stocks with earnings revision charts like Apple’s because the bar is always rising, which means that the stock will follow suit.</p>\n<p><b>Not all is well</b></p>\n<p>Apple, to be fair, does face a huge amount of risks that are outside of its control. Many of them cropped up since my last report on Apple and so I want to balance my bullish position on the stock with some sobering reality to ensure readers are well-equipped to make an informed decision about whether or not Apple is right for their portfolio.</p>\n<p>First, the FTC made the headlines a few weeks ago by appointing&nbsp;Lina Khan, an outspoken and noted big tech critic, who feels certain companies have too much control over the behaviors of consumers. This is a noteworthy development because if the FTC wants to go after big tech, Apple is a very logical early target. I don’t see it impacting iPhone or other hardware sales but services revenue? Absolutely. This is a longer-term threat since antitrust rules take time to create, but Apple shareholders need to take this threat seriously.</p>\n<p>The&nbsp;White Houseis apparently on board with this line of thinking, and the&nbsp;House&nbsp;is actually considering legislation that would undertake to reign in the perceived control of big tech companies, including Apple's tendency to pre-install its own apps on Apple devices. Would that stop consumers from just going to the app store and downloading them? No, but it certainly isn't a<i>positive</i>&nbsp;catalyst.</p>\n<p>Apple is facing a similar threat in&nbsp;Germany&nbsp;and other places in the developed world, so it isn’t just a problem at home. Germany is assessing if Apple has “competition violations” to be addressed. So the issue is the same one being faced in the US, and the only two outcomes are neutral (nothing happens), or negative (antitrust action is taken).</p>\n<p>Apple is also still very much beholden to the never-ending trade war between&nbsp;China&nbsp;and the US, as the two countries constantly jockey for position with the highest stakes the world has ever seen in such a scuffle. Apple’s production process is potentially at risk, depending upon how ugly things get, adding some geopolitical risk to the stock's outlook. This goes both ways, and China employs a lot of people and generates a lot of cash from Apple’s production. So I’m not sure it is as one-sided as it seems, but the geopolitical risk is never a good thing, and Apple’s manufacturing needs set it up for such a risk.</p>\n<p><b>Final thoughts</b></p>\n<p>I’ve enumerated a variety of potential issues Apple is facing, and I’ll be clear and say none of these are good things. The best possible outcome is that nothing changes, and the worst is that all come to fruition and Apple faces manufacturing challenges, as well as antitrust actions. These are real threats, but I also think they're already priced in.</p>\n<p>The threat of antitrust legislation or a trade war with China isn’t new by any stretch of the imagination and is not dissimilar to the threats that other tech giants like Amazon (AMZN), Alphabet (GOOG), or Facebook (FB) face every day. This is par for the course if you’re a dominant tech company, and Apple certainly is. I don’t want to ignore these potential negative catalysts, but I don’t want to overreact, either.</p>\n<p>Keep in mind also that Apple continues to move higher over time despite this bad news, which is what winning stocks do. The fact that it is shrugging off these huge potential negative catalysts reinforces the bullish stance I already had on the stock.</p>\n<p>I detailed my bullishness on the company’s revenue generation, margins, buybacks, valuation, and more in the&nbsp;prior piece, and nothing has changed there. So I don’t want to waste your time going through it again. However, my fundamental stance on Apple hasn’t changed in the past six weeks, and if anything, continued upward revisions in EPS estimates have strengthened the bull case.</p>\n<p>The important thing is that shareholders must be aware of external threats, but also that we are seeing Apple get to the end of its very bullish consolidation pattern at the same time that it typically begins a pre-earnings run higher.</p>\n<p>The bottom line is that I think Apple’s breakout is imminent, and that the pattern measures to $172 or so. This won’t happen overnight, but if you were looking to buy Apple, act quickly.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple: Act Quickly Before The Run To $172</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple: Act Quickly Before The Run To $172\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 14:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nApple faces many external threats from regulators in the developed world.\nBut I see these as largely priced in, although they remain a threat longer term.\nApple is on the cusp of what should ...</p>\n\n<a href=\"https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4437069-apple-act-quickly-before-the-run-to-172","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110936297","content_text":"Summary\n\nApple faces many external threats from regulators in the developed world.\nBut I see these as largely priced in, although they remain a threat longer term.\nApple is on the cusp of what should be a pre-earnings run and an imminent breakout of a bullish consolidation pattern.\n\nfMing Yeung/Getty Images News\nI have made it no secret that I’m a big fan of Apple(AAPL). In fact, I wrote a very bullish piece about six weeks ago, detailing how I thought Apple was in the process of consolidating before a big breakout. In this article, I want to update readers on the progress of that, as well as addressing some concerns that could be potentially bearish. But the spoiler alert is that I’m still very much in the camp of Apple setting up a breakout, and I think the company’s typical pre-earnings move is likely the catalyst to see that happen.\nSource: StockCharts\nTo start, I’ve annotated the same ascending triangle formation I noted six weeks ago, because it is still very much in play. The stock is very near the top of the triangle today, so what happens when/if it gets to $136/$137 will determine if the breakout is imminent or if we need at least one more test of the rising trend line that forms the bottom of the triangle. Whether that occurs or not doesn’t change my outlook; only the timing of it.\nAscending triangles measure upside targets on breakouts equal to the top and bottom of the widest part of the triangle. In this case, the top of the triangle is $137 and the bottom of the triangle, which was set in September of last year, was $102. That means that this triangle pattern has a measured price target – after the breakout – of $35 higher ($137 minus $102), and with the breakout point being $137 or so, that implies we canexpect Apple to hit $172, give or take. Now, that won’t happen immediately, of course, but that’s the kind of opportunity at hand here.\nWhat do you need to look for on a breakout? First, price action needs to decisively clear the breakout level of $137 and close above it. In addition, you want to see rising volume on the breakout – I’ve annotated declining volume in the triangle period, which is normal behavior – and you want to see rising momentum, we’ve got rising momentum today. So I’d expect a breakout to continue that, but these are the things you want to see on a breakout to ensure it has staying power.\nFinally, you’ll notice that I’ve added blue circles on the chart, and those represent the start of the ~4-week period prior to an earnings release. Apple has beenveryreliable in the past couple of years in terms of rallying into an earnings report, and I have no reason to think that will change. The gains are fairly large in most cases, with about half of them being in the double-digits, so this is a real catalyst for higher prices.\nThe important thing to note is that we are about four weeks from the third quarter report, which typically takes place at the end of July. We are also at the top of the ascending triangle, which means that even a small pre-earnings run will likely result in a breakout, and that’s why I think the breakout is very near.\nTo be clear, I’m reiterating my prior thesis that an ascending triangle breakout is coming; I just think we have a very clear catalyst now to make it sooner than later. I see the stock rallying into the earnings report, and if history is a guide, Apple will destroy expectations once again. In short, all is going to plan.\nThe risk is that if Apple does break out of the triangle and earnings aren’t very good, the pattern could fail. That would negate my $172 price target, and we’d have to reassess. For now, the odds of that look low, and I’m still full steam ahead on the breakout coming pre-earnings.\nWhy does Apple rally pre-earnings?\nTo put it succinctly, Apple rallies pre-earnings because no matter how much analysts raise their targets going into the reports, Apple finds a way to beat them.\nSource:Seeking Alpha\nThis is three years’ worth of data showing how Apple beats expectations, and by enormous margins in some cases. Apple is one of the largest and most-followed companies that has ever existed. So if any company should have an analyst community that knows how it will perform each quarter, it would be this one. However, its dominance in hardware and services revenue has proven too much for analysts over time to keep up with.\nKeep in mind a risk here is that if Apple does finally miss expectations, I have to imagine the stock will react extremely poorly. Thus, there is certainly risk in owning Apple through the earnings report, as with any other stock. But the company’s history of smashing expectations – particularly in the past year – means the odds of this are fairly low. Still, something to keep in mind from a risk perspective.\nIn terms of a catalyst for rallying into the July report, Apple continues to see analysts scramble to keep up with its rising fortunes.\nSource:Seeking Alpha\nThe sharp upward revisions that began last summer continue unabated, and Apple’s earnings trajectory remains very much intact. I detailed this in my last piece so I’m simply saying that nothing has changed on this front, and that’s a very good thing.\nSource:Seeking Alpha\nI think you’ll struggle to find a company with a better earnings revision schedule, as the past three months have seen 36 EPS revisions, and100%of them were upward. That shows just how strong Apple’s earnings trajectory is, as analysts scramble to meet Apple’s outstanding performances. I love stocks with earnings revision charts like Apple’s because the bar is always rising, which means that the stock will follow suit.\nNot all is well\nApple, to be fair, does face a huge amount of risks that are outside of its control. Many of them cropped up since my last report on Apple and so I want to balance my bullish position on the stock with some sobering reality to ensure readers are well-equipped to make an informed decision about whether or not Apple is right for their portfolio.\nFirst, the FTC made the headlines a few weeks ago by appointing Lina Khan, an outspoken and noted big tech critic, who feels certain companies have too much control over the behaviors of consumers. This is a noteworthy development because if the FTC wants to go after big tech, Apple is a very logical early target. I don’t see it impacting iPhone or other hardware sales but services revenue? Absolutely. This is a longer-term threat since antitrust rules take time to create, but Apple shareholders need to take this threat seriously.\nThe White Houseis apparently on board with this line of thinking, and the House is actually considering legislation that would undertake to reign in the perceived control of big tech companies, including Apple's tendency to pre-install its own apps on Apple devices. Would that stop consumers from just going to the app store and downloading them? No, but it certainly isn't apositive catalyst.\nApple is facing a similar threat in Germany and other places in the developed world, so it isn’t just a problem at home. Germany is assessing if Apple has “competition violations” to be addressed. So the issue is the same one being faced in the US, and the only two outcomes are neutral (nothing happens), or negative (antitrust action is taken).\nApple is also still very much beholden to the never-ending trade war between China and the US, as the two countries constantly jockey for position with the highest stakes the world has ever seen in such a scuffle. Apple’s production process is potentially at risk, depending upon how ugly things get, adding some geopolitical risk to the stock's outlook. This goes both ways, and China employs a lot of people and generates a lot of cash from Apple’s production. So I’m not sure it is as one-sided as it seems, but the geopolitical risk is never a good thing, and Apple’s manufacturing needs set it up for such a risk.\nFinal thoughts\nI’ve enumerated a variety of potential issues Apple is facing, and I’ll be clear and say none of these are good things. The best possible outcome is that nothing changes, and the worst is that all come to fruition and Apple faces manufacturing challenges, as well as antitrust actions. These are real threats, but I also think they're already priced in.\nThe threat of antitrust legislation or a trade war with China isn’t new by any stretch of the imagination and is not dissimilar to the threats that other tech giants like Amazon (AMZN), Alphabet (GOOG), or Facebook (FB) face every day. This is par for the course if you’re a dominant tech company, and Apple certainly is. I don’t want to ignore these potential negative catalysts, but I don’t want to overreact, either.\nKeep in mind also that Apple continues to move higher over time despite this bad news, which is what winning stocks do. The fact that it is shrugging off these huge potential negative catalysts reinforces the bullish stance I already had on the stock.\nI detailed my bullishness on the company’s revenue generation, margins, buybacks, valuation, and more in the prior piece, and nothing has changed there. So I don’t want to waste your time going through it again. However, my fundamental stance on Apple hasn’t changed in the past six weeks, and if anything, continued upward revisions in EPS estimates have strengthened the bull case.\nThe important thing is that shareholders must be aware of external threats, but also that we are seeing Apple get to the end of its very bullish consolidation pattern at the same time that it typically begins a pre-earnings run higher.\nThe bottom line is that I think Apple’s breakout is imminent, and that the pattern measures to $172 or so. This won’t happen overnight, but if you were looking to buy Apple, act quickly.","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897013387,"gmtCreate":1628862601349,"gmtModify":1631891607556,"author":{"id":"4087475573507020","authorId":"4087475573507020","authorIdStr":"4087475573507020","name":"PhewyPompipi","avatar":"https://static.tigerbbs.com/10a26daea90fabdea45079a2a026323c","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087475573507020"},"themes":[],"htmlText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","listText":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","text":"Things are certainly looking up! Would it ever hit close to Moderna like days before, closing nearly to 500?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/897013387","repostId":"1141206470","repostType":4,"repost":{"id":"1141206470","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628861824,"share":"https://www.laohu8.com/m/news/1141206470?lang=&edition=full","pubTime":"2021-08-13 21:37","market":"us","language":"en","title":"BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1141206470","media":"Tiger Newspress","summary":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster ","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Rise On Nod To Booster For Those With Weak Immunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stocks were up in&nbsp;early&nbsp;trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.</p>\n<p>BioNTech was up 3% and Moderna gained 3%, while Pfizer&nbsp;, which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/18d1d9877f2ba36a61eaf23f41b8914f\" tg-width=\"898\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n<p>Late on Thursday, the U.S. Food and Drug Administration&nbsp;authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.</p>\n<p>Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.</p>\n<p>Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141206470","content_text":"BioNTech and Moderna stocks were up in early trading following the FDA authorizing Covid-19 booster shots for people with weak immunity.\nBioNTech was up 3% and Moderna gained 3%, while Pfizer , which has jointly developed the two-dose mRNA vaccine with BioNTech, was up 2%.\n\nLate on Thursday, the U.S. Food and Drug Administration authorized a booster doseof vaccines from Pfizer Inc(PFE.N)and Moderna Inc(MRNA.O)for people with compromised immune systems.\nPfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.\nGoing forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}